Thank you to everyone who took part in our survey back in March ahead of the NICE review on RA drugs. With your help, these drugs are still available, however, the criteria to access them remains unchanged. NICE are missing the opportunity to improve patient care (read more on this at bit.ly/1QYFVa9).
We are now asking them to widen the eligibility criteria (in line with the rest of Western Europe) which would allow more people to access these life changing drugs.
We need to hear from people in the UK with 'moderate to severe' rheumatoid arthritis (DAS score somewhere between 3.2 and 5.1) who are NOT currently eligible for biologic therapy.
If this includes you, please find out more about how you can help at nras.org.uk/news/nice-revie...
Your experiences will accompany our submission to NICE relating to the Multiple Technology Appraisal consultation document which was published for public consultation recently.
Thank you for your help!
NRAS Digital Media Manager & Community Admin